Gene · 4070
Papers3,230
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
701 to 720 of 3,230
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Canadian Expert Recommendations on Safety Overview and Toxicity Management Strategies for Sacituzumab Govitecan Based on Use in Metastatic Triple-Negative Breast Cancer. | Curr Oncol | 2024 | 39330050 | PubTator, text mining | PubMed |
| Targeted and combination immunotherapies using biologics for gastric cancer: the state-of-the-art. | Expert Opin Biol Ther | 2024 | 39315517 | PubTator, text mining | PubMed |
Comparative Analysis and Future Prospects of Human Epidermal Growth Factor Receptor 2 (HER2) and Trophoblast Cell-Surface Antigen 2 (Trop-2) Targeted Antibody-Drug Conjugates in Breast Cancer Treatment. | Breast Cancer (Dove Med Press) | 2024 | 39310781 | PubTator, text mining | PubMed |
| Preliminary results from ASCENT-J02: a phase 1/2 study of sacituzumab govitecan in Japanese patients with advanced solid tumors. | Int J Clin Oncol | 2024 | 39302614 | PubTator, text mining | PubMed |
| Effect of a FOXO1 inhibitor on trophoblast differentiation from human pluripotent stem cells and ERV-associated gene expression. | Regen Ther | 2024 | 39290630 | PubTator, text mining | PubMed |
| Selection of trophoblast cell surface antigen 2-targeted aptamer for the development of cytotoxic aptamer-drug conjugate. | Int J Biol Macromol | 2024 | 39250993 | PubTator, text mining | PubMed |
| Identification of biomarker associated with Trop2 in breast cancer: implication for targeted therapy. | Discov Oncol | 2024 | 39240479 | PubTator, text mining | PubMed |
| Revolutionizing triple-negative metastatic breast cancer treatment: sacituzumab Govitecan's role in advancing chemotherapy. | Ann Med Surg (Lond) | 2024 | 39238964 | PubTator, text mining | PubMed |
| Phase 1a study of ESG401, a Trop2 antibody-drug conjugate, in patients with locally advanced/metastatic solid tumors. | Cell Rep Med | 2024 | 39216478 | PubTator, text mining | PubMed |
| Sacituzumab govitecan in triple-negative breast cancer: from bench to bedside, and back. | Front Immunol | 2024 | 39211043 | PubTator, text mining | PubMed |
| Sacituzumab govitecan for hormone receptor-positive HER2-negative advanced breast cancer. | Expert Rev Anticancer Ther | 2024 | 39210557 | PubTator, text mining | PubMed |
| Sacituzumab govitecan response in extensive leptomeningeal carcinomatosis from triple-negative breast cancer: a case report. | Front Oncol | 2024 | 39188688 | PubTator, text mining | PubMed |
| TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer Progressing After Previous Checkpoint Inhibitor Therapy. | J Clin Oncol | 2024 | 39186707 | PubTator, text mining | PubMed |
| TROP2 in colorectal carcinoma: associations with histopathology, molecular phenotype, and patient prognosis. | J Pathol Clin Res | 2024 | 39177576 | PubTator, text mining | PubMed |
| Trop2-targeted therapy in breast cancer. | Biomark Res | 2024 | 39135109 | PubTator, text mining | PubMed |
| Sacituzumab Govitecan in patients with breast cancer brain metastases and recurrent glioblastoma: a phase 0 window-of-opportunity trial. | Nat Commun | 2024 | 39112464 | PubTator, text mining | PubMed |
| Sacituzumab govitecan in heavily pretreated, platinum-resistant high grade serous ovarian cancer. | Gynecol Oncol Rep | 2024 | 39108617 | PubTator, text mining | PubMed |
| Antibody-drug conjugates treatment of small cell lung cancer: advances in clinical research. | Discov Oncol | 2024 | 39090431 | PubTator, text mining | PubMed |
| Sacituzumab Govitecan Demonstrates Efficacy across Tumor Trop-2 Expression Levels in Patients with Advanced Urothelial Cancer. | Clin Cancer Res | 2024 | 39086310 | PubTator, text mining | PubMed |
| Single-cell profiling of surface glycosphingolipids opens a new dimension for deconvolution of breast cancer intratumoral heterogeneity and phenotypic plasticity. | J Lipid Res | 2024 | 39084491 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4070/papers?page=36